Branch, A good antisense molecule is hard to find, TIBS, vol. 23, pp. 45-50, Feb. 1998.* |
Agrawal, Antisense oligonucleotides:towards clinical trials, TIBTECH, vol. 14, pp. 376-387, Oct. 1996.* |
Gewirtz et al., Facilitating oligonucleotide delivery: helping antisense deliver on its promise, PNAS, vol. 93, pp. 3161-3163, Apr. 1996.* |
Gerwirtz et al. PNAS 93:3161-3163 (1996).* |
Rojanasakul et al. Adv. Arag. Delivery Mer. 18:115-131 (1996).* |
Proceedings of the American Association for Cancer Research, vol. 32, Mar. 1991, p. 433, Brysch, W. et al. “Inhibiting c-erbB-2 overexpression in human mammary carcinoma cells with phosphorothioate oligodeoxynucleotides”. |
Gene Regulation: Biology of Antisens RNA and DNA; K.H. Schlingensiepen & W. Brysch; 1992; pp. 317-328; Phosphorothioate oligomers: Inhibitors of Oncogene Expression in Tumor Cells and Tools for Gene Function Analysis. |
Science, vol. 230, Dec. 6, 1985, Lancaster, PA; pp. 1132-1139 Coussens, L. et al.; “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location With Neu Oncogene”. |